Combination therapy of shinbaro and celecoxib improves joint pain and cartilage degradation in an osteoarthritis mouse model
Abstract
Osteoarthritis is characterized by cartilage degeneration and joint pain, and celecoxib is widely used to treat osteoarthritis, but it has the risk of side effects. We investigated the effect of Shinbaro, a herbal medicine, combined with celecoxib in osteoarthritis. In vitro, primary chondrocytes treated with Shinbaro (200 μg/mL) or celecoxib (0.5 or 1 μM) in the presence of interleukin (IL)-1β (1 ng/mL) for 24 and 48 h were analyzed for cell viability, gene expression, and protein levels. In vivo, mice with osteoarthritis induced via destabilization of the medial meniscus (DMM) surgery were treated with Shinbaro (100 mg/kg) and/or celecoxib (15 or 30 mg/kg) five times weekly for 8 weeks (n = 7/groups; total n = 42). Cartilage degradation and inflammation were evaluated through behavioral tests, Osteoarthritis Research Society International (OARSI) scoring, and immunofluorescence. The combined treatment did not affect cell viability but reduced the IL-1β-induced expression of extracellular matrix (ECM)-degrading enzymes (matrix metallopeptidase 13 and a disintegrin and metalloproteinase with thrombospondin motifs 5) in chondrocytes. It also inhibited IL-1β-induced mitogen-activated protein kinase pathway activation, showing a synergistic reduction in pro-inflammatory markers compared to single treatments. In a DMM-induced osteoarthritis mouse model, the combined treatment improved weight distribution, reduced mechanical allodynia, and protected against cartilage degradation,…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.